Pub Date : 2020-10-01DOI: 10.1016/j.medmal.2019.09.013
S. Snopkova , M. Matyskova , K. Havlickova , J. Jarkovsky , M. Svoboda , J. Zavrelova , R. Svacinka , M. Penka , P. Husa
Objectives
HIV-infected individuals are at higher risk of non-AIDS diseases associated with procoagulant status. Microparticles are elevated in disorders associated with thrombosis (e.g., cardiovascular diseases). We investigated the association between microparticle levels in untreated and treated HIV-infected subjects, and determined the association with immune status, viral replication, and duration of antiretroviral therapy.
Patients and methods
We included 144 HIV-infected subjects, including 123 on antiretroviral therapy (ART) and 21 before treatment initiation. A control group of 40 HIV-negative healthy adults matched for age and sex was used for comparison of microparticle levels. Treated subjects were divided into five groups depending on the period of antiretroviral exposure. Statistically significant differences were determined by Kruskal–Wallis test and Chi2 test. The relation between microparticles and other parameters was assessed using Spearman's coefficient of correlation.
Results
Microparticle levels were significantly higher in treated and untreated HIV-infected subjects than in non-HIV-infected controls (P< 0.001). The microparticle level was similar between the groups on treatment (P = 0.913). No association between the microparticle level and CD4+ count, CD4+/CD8+ ratio, number of HIV-1 RNA copies, or duration of exposure to antiretroviral treatment was observed.
Conclusion
Increased levels of microparticles may be due to processes independent of viral replication and CD4+ cell count, and microparticle release might persist even during viral suppression by antiretroviral treatment. Elevated microparticle levels might occur in response to other triggers.
{"title":"Increasing procoagulant activity of circulating microparticles in patients living with HIV","authors":"S. Snopkova , M. Matyskova , K. Havlickova , J. Jarkovsky , M. Svoboda , J. Zavrelova , R. Svacinka , M. Penka , P. Husa","doi":"10.1016/j.medmal.2019.09.013","DOIUrl":"10.1016/j.medmal.2019.09.013","url":null,"abstract":"<div><h3>Objectives</h3><p>HIV-infected individuals are at higher risk of non-AIDS diseases associated with procoagulant status. Microparticles are elevated in disorders associated with thrombosis (e.g., cardiovascular diseases). We investigated the association between microparticle levels in untreated and treated HIV-infected subjects, and determined the association with immune status, viral replication, and duration of antiretroviral therapy.</p></div><div><h3>Patients and methods</h3><p>We included 144 HIV-infected subjects, including 123 on antiretroviral therapy (ART) and 21 before treatment initiation. A control group of 40 HIV-negative healthy adults matched for age and sex was used for comparison of microparticle levels. Treated subjects were divided into five groups depending on the period of antiretroviral exposure. Statistically significant differences were determined by Kruskal–Wallis test and Chi<sup>2</sup> test. The relation between microparticles and other parameters was assessed using Spearman's coefficient of correlation.</p></div><div><h3>Results</h3><p>Microparticle levels were significantly higher in treated and untreated HIV-infected subjects than in non-HIV-infected controls (<em>P</em> <em><</em> <!-->0.001). The microparticle level was similar between the groups on treatment (<em>P</em> <!-->=<!--> <!-->0.913). No association between the microparticle level and CD4+ count, CD4+/CD8+ ratio, number of HIV-1 RNA copies, or duration of exposure to antiretroviral treatment was observed.</p></div><div><h3>Conclusion</h3><p>Increased levels of microparticles may be due to processes independent of viral replication and CD4+ cell count, and microparticle release might persist even during viral suppression by antiretroviral treatment. Elevated microparticle levels might occur in response to other triggers.</p></div>","PeriodicalId":18464,"journal":{"name":"Medecine et maladies infectieuses","volume":"50 7","pages":"Pages 555-561"},"PeriodicalIF":5.0,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.medmal.2019.09.013","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86284567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-10-01DOI: 10.1016/j.medmal.2020.03.003
G. Chieffo , S. Corsia , G. Rougereau , M. Enser , L.J. Eyrolle , S. Kernéis , P. Morand , J. Loubinoux , R. Gauzit , P. Leclerc , P. Wipff , Y. Allanore , P. Anract , D. Salmon
Objectives
One-stage replacement arthroplasty for treatment of periprosthetic joint infection (PJI) results in similar cure rate than two-stage (around 85–92%), but antibiotic therapy duration is not well established. The aim of this study was to evaluate the efficacy of a short six-week antibiotic course in periprosthetic joint infections after onstage exchange.
Patients and methods
Retrospective, observational study conducted at Orthopaedic Department of Cochin Hospital, Paris, between 1st January 2010 and 31 December 2015. Patients with a microbiologically proven PJI, treated with one-stage replacement and 6 weeks (+/1week) of antimicrobial therapy were included. Pearson's-χ2 and Wilcoxon tests were used to compare categorical and continuous variables.
Results
Fifty patients with periprosthetic joint infections (42 hip, 8 knee PJI) treated with one-stage replacement arthroplasty were included. Median age was 69.3 years (IQR 24.5–97.4). Infections occurred after a mean of 36 months (IQR 1–216). Bone biopsy cultures were positive for Staphylococcus spp. in 29 patients (58%), Cutibacterium acnes in 19 (38%), Gram-negative bacilli in 6 (12%). Polymicrobial infections occurred in 12 (24%). Intravenous antibiotics were administered for a median of 11 days (IQR 4–45) and 46 patients (92%) were switched to an oral therapy. Medium follow-up was of 32 months (IQR 12–101). Overall remission rate was 90%.
Conclusions
A six-week course of antibiotics in knee and hip PJIs treated with one-stage RA has a satisfactory remission rate in this open study.
{"title":"Six-week antibiotic therapy after one-stage replacement arthroplasty for hip and knee periprosthetic joint infection","authors":"G. Chieffo , S. Corsia , G. Rougereau , M. Enser , L.J. Eyrolle , S. Kernéis , P. Morand , J. Loubinoux , R. Gauzit , P. Leclerc , P. Wipff , Y. Allanore , P. Anract , D. Salmon","doi":"10.1016/j.medmal.2020.03.003","DOIUrl":"10.1016/j.medmal.2020.03.003","url":null,"abstract":"<div><h3>Objectives</h3><p>One-stage replacement arthroplasty for treatment of periprosthetic joint infection (PJI) results in similar cure rate than two-stage (around 85–92%), but antibiotic therapy duration is not well established. The aim of this study was to evaluate the efficacy of a short six-week antibiotic course in periprosthetic joint infections after onstage exchange.</p></div><div><h3>Patients and methods</h3><p>Retrospective, observational study conducted at Orthopaedic Department of Cochin Hospital, Paris, between 1st January 2010 and 31 December 2015. Patients with a microbiologically proven PJI, treated with one-stage replacement and 6 weeks (+/1week) of antimicrobial therapy were included. Pearson's-<em>χ</em><sup>2</sup> and Wilcoxon tests were used to compare categorical and continuous variables.</p></div><div><h3>Results</h3><p>Fifty patients with periprosthetic joint infections (42 hip, 8 knee PJI) treated with one-stage replacement arthroplasty were included. Median age was 69.3 years (IQR 24.5–97.4). Infections occurred after a mean of 36 months (IQR 1–216). Bone biopsy cultures were positive for <em>Staphylococcus</em> spp. in 29 patients (58%), <em>Cutibacterium acnes</em> in 19 (38%), Gram-negative bacilli in 6 (12%). Polymicrobial infections occurred in 12 (24%). Intravenous antibiotics were administered for a median of 11 days (IQR 4–45) and 46 patients (92%) were switched to an oral therapy. Medium follow-up was of 32 months (IQR 12–101). Overall remission rate was 90%.</p></div><div><h3>Conclusions</h3><p>A six-week course of antibiotics in knee and hip PJIs treated with one-stage RA has a satisfactory remission rate in this open study.</p></div>","PeriodicalId":18464,"journal":{"name":"Medecine et maladies infectieuses","volume":"50 7","pages":"Pages 567-574"},"PeriodicalIF":5.0,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.medmal.2020.03.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37830063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-10-01DOI: 10.1016/j.medmal.2020.06.001
M. Autissier , G. Guiraud , Y. Lévy
{"title":"COVID reverse transcriptase PCR in private laboratories: From theory to reality","authors":"M. Autissier , G. Guiraud , Y. Lévy","doi":"10.1016/j.medmal.2020.06.001","DOIUrl":"10.1016/j.medmal.2020.06.001","url":null,"abstract":"","PeriodicalId":18464,"journal":{"name":"Medecine et maladies infectieuses","volume":"50 7","pages":"Pages 627-629"},"PeriodicalIF":5.0,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.medmal.2020.06.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38042262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-10-01DOI: 10.1016/j.medmal.2019.09.011
K. Simon , P.-Y. Cordier , V. Pommier de Santi , A. Luft , C. Brossier , E. Peytel , F. Simon
Objectives
Medical evacuations from foreign settings are a major health and strategic problem for the armed forces. This work aimed to study the characteristics of French military evacuations due to infectious diseases.
Patients and methods
We performed a retrospective study based on the registers of the French operational military staff for health to assess the characteristics of the strategic medical evacuation of French armed forces members on missions abroad between January 1, 2011 and December 31, 2016.
Results
Out of 4633 included cases, 301 medical evacuations (6.5%) were carried out due to infectious situations. More than half of patients were repatriated to surgical wards (162 patients, 54%), 108 patients (36%) to medical wards, 21 patients (7%) to intensive care units, six patients (2%) to an armed forces medical center, and four files (1%) were incomplete. Among infectious emergencies, malaria led to 30 evacuations (10%) including 11 to intensive care units and one death before evacuation. Infectious diseases requiring medical evacuation were most often mild and community-acquired. Most soldiers were evacuated without medical assistance.
Conclusions
Infectious diseases during missions and medical repatriations carried out for infectious reasons are important epidemiological indicators to monitor. They make it possible to adapt preventive measures, training, and diagnostic and therapeutic tools which can be made available to front-line military physicians.
{"title":"Medical evacuations of members of the French armed forces for infectious diseases in foreign operations","authors":"K. Simon , P.-Y. Cordier , V. Pommier de Santi , A. Luft , C. Brossier , E. Peytel , F. Simon","doi":"10.1016/j.medmal.2019.09.011","DOIUrl":"10.1016/j.medmal.2019.09.011","url":null,"abstract":"<div><h3>Objectives</h3><p>Medical evacuations from foreign settings are a major health and strategic problem for the armed forces. This work aimed to study the characteristics of French military evacuations due to infectious diseases.</p></div><div><h3>Patients and methods</h3><p>We performed a retrospective study based on the registers of the French operational military staff for health to assess the characteristics of the strategic medical evacuation of French armed forces members on missions abroad between January 1, 2011 and December 31, 2016.</p></div><div><h3>Results</h3><p>Out of 4633 included cases, 301 medical evacuations (6.5%) were carried out due to infectious situations. More than half of patients were repatriated to surgical wards (162 patients, 54%), 108 patients (36%) to medical wards, 21 patients (7%) to intensive care units, six patients (2%) to an armed forces medical center, and four files (1%) were incomplete. Among infectious emergencies, malaria led to 30 evacuations (10%) including 11 to intensive care units and one death before evacuation. Infectious diseases requiring medical evacuation were most often mild and community-acquired. Most soldiers were evacuated without medical assistance.</p></div><div><h3>Conclusions</h3><p>Infectious diseases during missions and medical repatriations carried out for infectious reasons are important epidemiological indicators to monitor. They make it possible to adapt preventive measures, training, and diagnostic and therapeutic tools which can be made available to front-line military physicians.</p></div>","PeriodicalId":18464,"journal":{"name":"Medecine et maladies infectieuses","volume":"50 7","pages":"Pages 545-554"},"PeriodicalIF":5.0,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.medmal.2019.09.011","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79817360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-09-01DOI: 10.1016/j.medmal.2020.06.063
S. Zaghbib, M. Chakroun, A. Saadi, S. Zouari, A. Bouzouita, H. Ayed, M. Chebil, A. Ferjani, I. Boutiba
Introduction
La prévalence des infections associées aux soins à entérobactéries productrices de carbapénémases (EPC) est en augmentation dans le monde. Ces infections, difficiles à traiter et souvent source d’impasses thérapeutiques, représentent un danger pour les patients avec un risque d’épidémies hospitalières pouvant devenir incontrôlables.
Matériels et méthodes
Une étude rétrospective a été menée entre janvier 2015 et décembre 2019, portant sur les patients qui ont été hospitalisés au service d’urologie chez qui une EPC a été identifiée sur l’examen cytobactériologique des urines (ECBU). Les caractéristiques épidémiologiques, cliniques et bactériologiques de ces infections ont été étudiées.
Résultats
Au cours de la période d’étude, nous avons identifié 25 patients porteurs d’EPC. L’âge moyen était de 50,5 ans. Une hospitalisation dans les 3 mois précédents a été retrouvée dans 11 cas (44 %), la prise d’antibiotiques dans les 6 mois précédant l’infection a été retrouvée dans 13 cas (52 %), et 11 patients (44 %) avaient un ECBU positif à un autre germe dans les 12 mois précédant l’infection. Au cours de l’hospitalisation, un geste urologique a été réalisé dans 20 cas (80 %), un matériel étranger urologique était en place dans 15 cas (60 %) et le délai moyen entre l’hospitalisation et l’infection était de 12 jours ± 4,8. Sur le plan bactériologique, les souches identifiées étaient K. pneumoniae (n = 20), E. cloacae (n = 2), E. coli (n = 2) et R. terrigena (n = 1). L’étude de la sensibilité aux antibiotiques a montré qu’elles étaient toutes résistantes à l’ertapénème, que 10 l’étaient à l’imipénème (40 %) et que 13 l’étaient au méropénème (52 %). Par ailleurs, toutes les souches étaient résistantes aux céphalosporines de 3e génération et sept l’étaient à l’amikacine (28 %). Une souche était résistante à la colistine (étudiée dans 18 cas), et quatre souches l’étaient à la tigecycline (étudiée dans 21 cas). Cliniquement, les EPC étaient responsables d’une bactériurie asymptomatique dans 14 cas (56 %), et d’une infection déclarée dans 11 cas (44 %), le plus souvent une pyélonéphrite aiguë (5 cas). Deux patients ont présenté un choc septique dont un est décédé des suites de l’infection. En cas d’infection déclarée (11 cas), une double antibiothérapie adaptée a été prescrite, associant colistine/amikacine(cinq cas), colistine/imipeneme (quatre cas) et imipeneme/amikacine (deux cas).
Conclusion
Les EPC représentent une menace réelle et préoccupante car elles sont capables de provoquer des infections contre lesquelles les moyens thérapeutiques sont extrêmement limités, de se disséminer rapidement et possèdent un potentiel épidémiogène important. Les bonnes pratiques d’hygiène hospitalière son
{"title":"Caractéristiques épidémiologiques et cliniques des infections à entérobactéries productrices de carbapénémases en urologie","authors":"S. Zaghbib, M. Chakroun, A. Saadi, S. Zouari, A. Bouzouita, H. Ayed, M. Chebil, A. Ferjani, I. Boutiba","doi":"10.1016/j.medmal.2020.06.063","DOIUrl":"10.1016/j.medmal.2020.06.063","url":null,"abstract":"<div><h3>Introduction</h3><p>La prévalence des infections associées aux soins à entérobactéries productrices de carbapénémases (EPC) est en augmentation dans le monde. Ces infections, difficiles à traiter et souvent source d’impasses thérapeutiques, représentent un danger pour les patients avec un risque d’épidémies hospitalières pouvant devenir incontrôlables.</p></div><div><h3>Matériels et méthodes</h3><p>Une étude rétrospective a été menée entre janvier 2015 et décembre 2019, portant sur les patients qui ont été hospitalisés au service d’urologie chez qui une EPC a été identifiée sur l’examen cytobactériologique des urines (ECBU). Les caractéristiques épidémiologiques, cliniques et bactériologiques de ces infections ont été étudiées.</p></div><div><h3>Résultats</h3><p>Au cours de la période d’étude, nous avons identifié 25 patients porteurs d’EPC. L’âge moyen était de 50,5 ans. Une hospitalisation dans les 3 mois précédents a été retrouvée dans 11 cas (44 %), la prise d’antibiotiques dans les 6 mois précédant l’infection a été retrouvée dans 13 cas (52 %), et 11 patients (44 %) avaient un ECBU positif à un autre germe dans les 12 mois précédant l’infection. Au cours de l’hospitalisation, un geste urologique a été réalisé dans 20 cas (80 %), un matériel étranger urologique était en place dans 15 cas (60 %) et le délai moyen entre l’hospitalisation et l’infection était de 12<!--> <!-->jours<!--> <!-->±<!--> <!-->4,8. Sur le plan bactériologique, les souches identifiées étaient <em>K. pneumoniae</em> (<em>n</em> <!-->=<!--> <!-->20), <em>E. cloacae</em> (<em>n</em> <!-->=<!--> <!-->2), <em>E. coli</em> (<em>n</em> <!-->=<!--> <!-->2) et <em>R. terrigena</em> (<em>n</em> <!-->=<!--> <!-->1). L’étude de la sensibilité aux antibiotiques a montré qu’elles étaient toutes résistantes à l’ertapénème, que 10 l’étaient à l’imipénème (40 %) et que 13 l’étaient au méropénème (52 %). Par ailleurs, toutes les souches étaient résistantes aux céphalosporines de 3<sup>e</sup> génération et sept l’étaient à l’amikacine (28 %). Une souche était résistante à la colistine (étudiée dans 18 cas), et quatre souches l’étaient à la tigecycline (étudiée dans 21 cas). Cliniquement, les EPC étaient responsables d’une bactériurie asymptomatique dans 14 cas (56 %), et d’une infection déclarée dans 11 cas (44 %), le plus souvent une pyélonéphrite aiguë (5 cas). Deux patients ont présenté un choc septique dont un est décédé des suites de l’infection. En cas d’infection déclarée (11 cas), une double antibiothérapie adaptée a été prescrite, associant colistine/amikacine(cinq cas), colistine/imipeneme (quatre cas) et imipeneme/amikacine (deux cas).</p></div><div><h3>Conclusion</h3><p>Les EPC représentent une menace réelle et préoccupante car elles sont capables de provoquer des infections contre lesquelles les moyens thérapeutiques sont extrêmement limités, de se disséminer rapidement et possèdent un potentiel épidémiogène important. Les bonnes pratiques d’hygiène hospitalière son","PeriodicalId":18464,"journal":{"name":"Medecine et maladies infectieuses","volume":"50 6","pages":"Page S37"},"PeriodicalIF":5.0,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.medmal.2020.06.063","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42067159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-09-01DOI: 10.1016/j.medmal.2020.06.257
M. Pichon, G. Motillon, J. Cremniter, J. Faure, P. Vasseur, D. Tougeron, C. Burucoa
{"title":"Distribution d’Helicobacter pylori : où et comment biopsier pour détecter l’infection et l’antibiorésistance ?","authors":"M. Pichon, G. Motillon, J. Cremniter, J. Faure, P. Vasseur, D. Tougeron, C. Burucoa","doi":"10.1016/j.medmal.2020.06.257","DOIUrl":"https://doi.org/10.1016/j.medmal.2020.06.257","url":null,"abstract":"","PeriodicalId":18464,"journal":{"name":"Medecine et maladies infectieuses","volume":"8 1","pages":""},"PeriodicalIF":5.0,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74148150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-09-01DOI: 10.1016/j.medmal.2020.06.476
M. Ruellan, A. Frachon, J. Philippe, K. Kpossou, B. Nsitou, S. Diamantis, J. Eff, N. Vignier
{"title":"Une consultation dédiée à la prise en charge des mineurs isolés étrangers : une opportunité de rattrapage vaccinal et d’entretien de santé sexuelle et globale","authors":"M. Ruellan, A. Frachon, J. Philippe, K. Kpossou, B. Nsitou, S. Diamantis, J. Eff, N. Vignier","doi":"10.1016/j.medmal.2020.06.476","DOIUrl":"https://doi.org/10.1016/j.medmal.2020.06.476","url":null,"abstract":"","PeriodicalId":18464,"journal":{"name":"Medecine et maladies infectieuses","volume":"233 1","pages":""},"PeriodicalIF":5.0,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74687869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-09-01DOI: 10.1016/j.medmal.2020.06.380
É. Seringe, A. Deslandes, K. Lebascle, P. Astagneau
{"title":"Couverture vaccinale antigrippale des professionnels de santé en Île-de-France : qu’en est-il dans les établissements de santé, dans les établissements médicosociaux et en ville ?","authors":"É. Seringe, A. Deslandes, K. Lebascle, P. Astagneau","doi":"10.1016/j.medmal.2020.06.380","DOIUrl":"https://doi.org/10.1016/j.medmal.2020.06.380","url":null,"abstract":"","PeriodicalId":18464,"journal":{"name":"Medecine et maladies infectieuses","volume":"268 1","pages":""},"PeriodicalIF":5.0,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74726194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-09-01DOI: 10.1016/j.medmal.2020.06.232
H. Brahimi, S. Benchouk
{"title":"Épidémie de fièvre typhoïde en 2019","authors":"H. Brahimi, S. Benchouk","doi":"10.1016/j.medmal.2020.06.232","DOIUrl":"https://doi.org/10.1016/j.medmal.2020.06.232","url":null,"abstract":"","PeriodicalId":18464,"journal":{"name":"Medecine et maladies infectieuses","volume":"14 1","pages":""},"PeriodicalIF":5.0,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75312232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号